Your browser doesn't support javascript.
loading
[Renal aspects of sodium glucose cotransporter 2 inhibitors]. / Les inhibiteurs du cotransporteur SGLT2 comme nouveau traitement du diabète: aspects rénaux.
Rev Med Suisse ; 11(463): 488-92, 2015 Feb 25.
Article en Fr | MEDLINE | ID: mdl-25898456
ABSTRACT
It has been known for centuries that the kidneys play a role in glucose homeostasis, yet the underlying tubular mechanisms have only been recently identified by studying patients with familial glucosuria. These insights have lead to the commercialization of a novel class of oral antidiabetic agents named gliflozines. Gliflozines induce renal glucosuria by blocking the Na-glucose cotransporter SGLT2, localized in the proximal tubule, and allow a reduction of 0.5 to 1% of glycated hemoglobin. They also diminish proximal sodium reabsorption, and reduce the glomerular hyperfiltration that is often seen in the early stages of diabetes. Preliminary data suggest that they may decrease blood pressure and have renoprotective effects. This article provides an overview of the role of kidneys in glucose homeostasis and the renal effects of SGLT2-inhibitors.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Inhibidores del Cotransportador de Sodio-Glucosa 2 Límite: Humans Idioma: Fr Revista: Rev Med Suisse Asunto de la revista: MEDICINA Año: 2015 Tipo del documento: Article
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Inhibidores del Cotransportador de Sodio-Glucosa 2 Límite: Humans Idioma: Fr Revista: Rev Med Suisse Asunto de la revista: MEDICINA Año: 2015 Tipo del documento: Article